You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Last Updated: October 28, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,546,399

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,546,399
Title:Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
Inventor(s): Bruncko; Milan (Green Oaks, IL), Ding; Hong (Gurnee, IL), Doherty; George A. (Libertyville, IL), Elmore; Steven W. (Northbrook, IL), Hasvold; Lisa A. (Grayslake, IL), Hexamer; Laura (Grayslake, IL), Kunzer; Aaron R. (Schaumburg, IL), Song; Xiaohong (Grayslake, IL), Souers; Andrew J. (Evanston, IL), Sullivan; Gerard M. (Lake Villa, IL), Tao; Zhi-Fu (Gurnee, IL), Wang; Gary T. (Libertyville, IL), Wang; Le (Vernon Hills, IL), Wang; Xilu (Grayslake, IL), Wendt; Michael D. (Vernon Hills, IL), Mantei; Robert (Franklin, WI), Hansen; Todd M. (Grayslake, IL)
Assignee: Abbvie Inc. (North Chicago, IL)
Application Number:12/787,682
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,546,399
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 8,546,399

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Abbvie Inc VENCLEXTA venetoclax TABLET;ORAL 208573-001 Apr 11, 2016 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Abbvie Inc VENCLEXTA venetoclax TABLET;ORAL 208573-002 Apr 11, 2016 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Abbvie Inc VENCLEXTA venetoclax TABLET;ORAL 208573-003 Apr 11, 2016 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,546,399

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 076705   Start Trial
Argentina 079124   Start Trial
Argentina 109974   Start Trial
Australia 2010254160   Start Trial
Australia 2010354083   Start Trial
Australia 2015201117   Start Trial
Australia 2015202183   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.